Los Angeles Capital Management
AVTX icon

Los Angeles Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Los Angeles Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-36
Closed -$233K – 1507
2020
Q3 		$233K Sell
36
-9
-20% -$67.6K ﹤0.01% 1353
2020
Q2 		$335K Buy
45
+39
+650% +$283K ﹤0.01% 1251
2020
Q1 		$45K Buy
+6
New +$63.5K ﹤0.01% 1316

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Los Angeles Capital Management's AVTX Position: Q4 2020 in Review

Los Angeles Capital Management sold out of Avalo Therapeutics (AVTX) in Q4 2020, closing a stake of 36 shares — an estimated $233K sold.

Los Angeles Capital Management first reported a position in AVTX in Q1 2020 and held it in 3 quarters. The position peaked at $335K in Q2 2020. 53 funds tracked by Wall St. Rank hold AVTX as of Q4 2020.

  • Los Angeles Capital Management reported no remaining Avalo Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Los Angeles Capital Management sold 36 Avalo Therapeutics shares in Q4 2020, an estimated $233K.
  • Los Angeles Capital Management first reported a position in Avalo Therapeutics in Q1 2020 and held it in 3 quarters.
  • Los Angeles Capital Management's Avalo Therapeutics position peaked at $335K in Q2 2020.
  • 53 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2020.

Based on Los Angeles Capital Management's 13F filing for Q4 2020, filed 4 Feb 2021.